On 28th August 2023, Stayble Therapeutics announced the enrollment of the first patient in
CROMSOURCE Regulatory Newsletter January – March 2023
CROMSOURCE announces publication of its latest Regulatory Newsletter summarising important
Stayble Therapeutics receives approval to start Phase Ib clinical trial with STA363 for the treatment of herniated discs
On 28th February 2023, Stayble Therapeutics AB announced that the Company received approval
CROMSOURCE Regulatory Newsletter October – December 2022
CROMSOURCE announces publication of its latest Regulatory Newsletter summarising important
CROMSOURCE Regulatory Newsletter July – September 2022
CROMSOURCE announces publication of its latest Regulatory Newsletter summarising important
- 1
- 2
- 3
- …
- 6
- Next Page »